Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma
Saved in:
| Title: | Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma |
|---|---|
| Authors: | Ellis, Rodney J.1,2 rje2@po.cwru.edu, Vertocnik, Amy3, Kim, Edward3, Zhou, Hang3, Young, Benjamin3, Sodee, Bruce4, Fu, Pingfu5, Beddar, Sam3, Colussi, Valdir3, Spirnak, John P.6, Dinchman, Kurt H.6, Resnick, Martin2, Kinsella, Timothy J.3 |
| Source: | International Journal of Radiation Oncology, Biology, Physics. Oct2003, Vol. 57 Issue 2, p362-370. 9p. |
| Subjects: | Prostate cancer, Radioisotope brachytherapy, Exocrine glands, Health risk assessment |
| Abstract: | : PurposeTo evaluate 4-year biochemical outcomes for patients with prostate adenocarcinoma who underwent radioimmunoguided (Prostascint) permanent prostate brachytherapy.: Methods and materialsEighty patients with clinical T1C–T3A NxM0 prostate cancer underwent ProstaScint-guided prostate brachytherapy using either 103Pd or 125I between February 1997 and December 2000. Sixty-seven patients underwent prostate brachytherapy alone, whereas 13 patients received neoadjuvant hormonal manipulation before implantation. Risk factors (RF) included PSA >10, Stage ≥T2b, and Gleason grade ≥7. Sixty patients had low-risk disease (0 RF), 17 were intermediate risk (1 RF), and 3 were high risk (2 RF). Biochemical disease-free survival (bDFS) was calculated using the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria, a PSA cutoff of 1.0 ng/mL, and a PSA cutoff of 0.5 ng/mL.: ResultsFour-year bDFS for the entire cohort was 97.4% using the ASTRO consensus criteria. Low-risk patients (60) had a 4-year bDFS of 100%; intermediate- and high-risk patients (20 patients) were 89.2%. The hormonally nai¨ve group (67 patients) had a 4-year bDFS of 96.9% and a median PSA nadir of 0.2 ng/mL. Median time to nadir was 19.8 months (range: 1.9–53.2 months). For the neoadjuvant hormonal therapy group (13 patients), ASTRO-defined bDFS was 100%. Overall, 85.2% of patients had a posttreatment PSA ≤1.0 ng/mL, and 75.9% had a PSA ≤0.5 ng/mL at a median follow-up of 36 months.: ConclusionsAt a median follow-up of 36 months, ProstaScint-guided transperineal brachytherapy results in a high probability of actuarial 4-year biochemical disease-free survival for patients with localized prostate cancer. [Copyright &y& Elsevier] |
| Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
Be the first to leave a comment!
